Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Hydroxychloroquine × Dermatologic × Clear all

Phase

Status

Unknown 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4 Genitourinary 3 Breast 3 Gynecologic 2 Thoracic 1 Other solid neoplasm 1 Other 1 Lymphoid 1 Head & Neck 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 60 Nivolumab 54 Ipilimumab 29 Cyclophosphamide 21 Specimen Handling 16 Magnetic Resonance Spectroscopy 15 Biopsy 14 fludarabine 13 cemiplimab 13 Opdualag 12 Radiosurgery 11 relatlimab 10 Blood Specimen Collection 10 aldesleukin 9 Interleukin-2 8 binimetinib 7 Surgical Procedures, Operative 7 fludarabine phosphate 6 Radiotherapy 6 Paclitaxel 6 Immunotherapy 6 mogamulizumab 5 encorafenib 5 atezolizumab 5 Temozolomide 5 Standard of Care 5 Immunoglobulin G 5 CTLA-4 Antigen 5 Bevacizumab 5 toripalimab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04464759 2025-07-08

LIMIT

Abramson Cancer Center at Penn Medicine

Phase 1/2 Recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡